Biopharma | May 01, 2026
Laurus Labs FY26 revenue rises 23% to Rs 6,813 Crore; EBITDA surges 64%
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
Global survey reveals top workforce concerns, evolving strategic priorities, and key technology investment areas for life sciences manufacturers
This partnership marks a significant step for the Company towards establishing renewable energy power generation using hybrid open excess through solar and wind sources
When asked how to balance ESG with broader business goals, the panel was unanimous in its assessment that ESG is ‘good for business’
PSCI, a global non-profit organization, works with its members to ensure a positive environment that can improve global healthcare supply chains
Subscribe To Our Newsletter & Stay Updated
